FDA Approves Sanofi's Venglustat for Type 3 Gaucher Disease
The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi (SNY) for its drug venglustat, marketed as Infilbray. The medication is specifically indicated for treating the neurological manifestations associated with Type 3 Gaucher disease. The regulatory decision follows results from the Phase 3 LEAP2MONO clinical study. Data from this trial demonstrated that venglustat provided superior improvements in neurological symptoms compared to standard enzyme replacement therapies, marking a significant development for patients suffering from this specific subtype of the disease.

Tickers: $SNY